AbbVie Inc. vs Canon Inc.: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and Canon Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating Canon Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and Canon Inc. is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against ~$31B for Canon Inc., while their respective market capitalizations stand at $465.8B and $25.6B. AbbVie Inc. is headquartered in United States and Canon Inc. in Japan, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie became an independent public biopharmaceutical company in January 2013 after Abbott Laboratories separated its research-based pharmaceutical business. Humira initially dominated its portfolio. AbbVie has since added Pharmacyclics, Allergan, ImmunoGen, and Cerevel and now reports major portfolios in immunology, neuroscience, oncology, and aesthetics.

Canon Inc.: Canon is a diversified Japanese manufacturer organized into four business units. Printing (office multifunction devices, laser and inkjet printers, production presses) is the largest. Imaging includes EOS cameras, RF lenses, cinema cameras and Axis network cameras. Medical, built on the 2016 purchase of Toshiba Medical Systems, makes CT, MRI, ultrasound and X-ray equipment. Industrial supplies semiconductor and flat-panel lithography tools and Canon Tokki OLED deposition systems. The group had 321 consolidated subsidiaries and 165,547 employees at the end of 2025, and its shares trade on the Tokyo Stock Exchange under code 7751.

AbbVie Inc. and Canon Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and Canon Inc..

AbbVie Inc. business model: AbbVie earns revenue from global sales of prescription medicines and Allergan Aesthetics products. Its FY2025 portfolios were led by immunology at $30.406 billion, neuroscience at $10.767 billion, oncology at $6.655 billion, and aesthetics at $4.860 billion. The company funds internal research and supplements its pipeline through licensing and acquisitions.

Canon Inc. business model: Canon designs, builds and sells hardware, then earns recurring revenue from consumables, service contracts and software on the installed base. In 2025 the Printing Business Unit produced ~$16.7 billion (¥2,494.4 billion) of sales (54%), split between office multifunction devices (~$7.13 billion (¥1,063.7 billion)), prosumer laser and inkjet printers (~$6.66 billion (¥993.4 billion)) and production presses (~$2.93 billion (¥437.3 billion)); toner, ink and maintenance on machines already in the field account for much of that income. Imaging (~$7.07 billion (¥1,054.9 billion), 23%) covers EOS cameras and lenses (~$4.19 billion (¥625.5 billion)) plus network cameras and video software from Axis and Milestone (~$2.88 billion (¥429.4 billion)). Medical (~$3.89 billion (¥580.6 billion), 13%) sells CT, MRI, ultrasound and X-ray systems and service. Industrial (~$2.42 billion (¥361.1 billion), 8%) sells semiconductor and flat-panel lithography tools, Canon Tokki OLED deposition systems and sputtering equipment. Canon sells through regional companies such as Canon U.S.A., Canon Europe and Canon Marketing Japan, and spent ~$2.27 billion (¥339.3 billion), about 7.3% of sales, on R&D in 2025.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of Canon Inc..

AbbVie Inc. competitive advantage: AbbVie's scale rests on its immunology portfolio, specialist commercial infrastructure, approved products across several therapeutic areas, and acquired oncology, neuroscience, and aesthetics assets. Those strengths are offset by patent-expiration, clinical-development, safety, reimbursement, and pricing risks described in its Form 10-K.

Canon Inc. competitive advantage: Canon's edge is vertical integration in optics and imaging. It designs its own lenses, CMOS image sensors, print engines and image-processing chips, and builds much of its own production equipment. That depth shows in its patent output (seventh in U.S. patent grants in 2025 and in the top 10 for 42 straight years, according to IFI Claims) and in a camera business that has held the No. 1 interchangeable-lens share for 23 consecutive years. In printing, a large installed base of office devices produces recurring toner and service revenue that new entrants cannot easily copy.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and Canon Inc. each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuroscience programs, and Allergan added Botox, Vraylar, migraine products, eye care, and aesthetics.

Canon Inc. growth strategy: Phase VII sets 2030 sales targets for each unit: Printing ~$18.8 billion (¥2.8 trillion) (about 2% a year), Imaging ~$8.98 billion (¥1.34 trillion) (5%), Medical ~$5.03 billion (¥750 billion) (5%) and Industrial ~$4.02 billion (¥600 billion) (10%). Growth products named in the plan are nanoimprint lithography, photon-counting CT and industrial printing equipment. Canon merged Canon Medical Systems' operations into Canon Inc. on April 1, 2026, is taking Canon Electronics private to build a space business worth ~$134 million (¥20 billion) or more in sales by 2030, and wants emerging markets such as India, Indonesia, Africa, the Middle East and Latin America to rise from 10% to 15% of sales. In Printing it plans to cut production staff by 30% and factory space by 40% by 2028 and to outsource hardware that needs no special technology.

A closer look at the financial trajectory of AbbVie Inc. and Canon Inc. rounds out the comparison.

AbbVie Inc.: AbbVie reported $61.160 billion of FY2025 net revenue and $4.226 billion of net income. Skyrizi and Rinvoq generated $25.866 billion combined, while Humira declined to $4.540 billion after U.S. biosimilar entry. The 2020 Allergan acquisition added neuroscience and aesthetics revenue, and the 2024 ImmunoGen and Cerevel acquisitions added oncology and neuroscience assets.

Canon Inc.: Canon's sales fell from ~$27.3 billion (¥4,080.0 billion) in 2017, the first full year with Toshiba Medical, to ~$21.2 billion (¥3,160.2 billion) in 2020 as cameras and office printing shrank and the pandemic hit. They have grown every year since, reaching a record ~$31 billion (¥4,624.7 billion) in 2025 (+2.5%). Operating profit was ~$3.05 billion (¥455.4 billion) in 2025, a 9.8% margin, up from ~$1.87 billion (¥279.8 billion) in 2024, when a ~$1.11 billion (¥165.1 billion) goodwill impairment on the medical business cut net income to ~$1.07 billion (¥160.0 billion). Net income attributable to Canon Inc. more than doubled to ~$2.23 billion (¥332.1 billion) and EPS rose to ¥367.48. Canon paid a ¥160 dividend (42.9% payout), generated ~$1.6 billion (¥238.5 billion) of free cash flow and ended 2025 with ~$6.34 billion (¥946.2 billion) of interest-bearing debt, up from ~$4.45 billion (¥663.5 billion). By region, the Americas supplied 32% of 2025 sales, Europe 26%, Japan 21% and Asia and Oceania 21%. In July 2026, after record second-quarter sales, Canon guided to ~$32.2 billion (¥4,800.0 billion) of 2026 sales and ~$3.12 billion (¥465.0 billion) of operating profit.